Drugs / SOX Chemotherapy
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06939439 Comparator | Dec 2024 → Dec 2026 expected | gastric cancer | The First Affiliated Hospital with Nanjing Medical University | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOX Chemotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06939439 ↗ |
| Route | Intravenous | “oxaliplatin 130 mg/m² intravenously every 3 weeks” NCT06939439 ↗ |